In the fourth and final episode from ADA 2022, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.
Dr. Amy Licis details recent observations regarding potential underlying neurobiological reasons for sleep disturbance in pediatric patients with ADHD or autism.
The HTRA1 and CFH risk alleles, family history of AMD, the LOC387715 risk allele, and cardiovascular disease were all linked to an increased risk of AMD.
Intravenous opioid use for VOC decreased by 52% in inpatient services between 2017-2018, while oral opioid use increased.
C1M, C3M, and C4M were significantly reduced in patients with structuring disease.
In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Jasmine Gonzalvo, PharmD, joins hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss prevailing barriers in diabetes management, including access to new pharmacologic agents as well as newer diabetes technologies.
Dr. Karan Lal returns to discuss key identifiers of pediatric morphea, and how dermatologists can collaborate with doctors from different branches of medicine to treat the disease.
Currently many more patients undergo right heart catheterization than is necessary for diagnosing pulmonary hypertension in patients with systemic sclerosis.
Dr. Smith provides an overview of this rare group of diseases, its variations, and where to find additional support outside of clinical environments.
Dr. Lisa Arkin speaks to how evidence-based, expert opinion-led consensus treatment plans for scleroderma can help change the way patients and providers approach the disease.
Dr. Cordoro speaks on the prevalence of variants of scleroderma in children, and how provides can better recognize and treat the disease in pediatric populations.
In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, are joined by special guest Anjali Owens, MD. An assistant professor of medicine and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens takes our hosts on a deep dive into the current state of management for oHCM and the impact of the US FDA's approval of mavacamten.
Investigators suggested that additional studies could explore the rate of mental health services use in patients with scleroderma with a clinical diagnosis of major depressive disorder or other mental health disorders.
The data obtained from the study supported the idea that IL-6 could be used as a potential marker for judging the efficacy of SSc.
Despite this, investigators suggested better quality filtering of scleroderma content on YouTube.
There is a growing body of evidence showing the value of rituximab in the treatment of SSc-ILD.
In our second special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, hosts Drs. Diana Isaacs and Natalie Bellini are joined by Gary Scheiner, MS, CDE. Clinical director of Integrated Diabetes Services, author of multiple books, including Think Like a Pancreas: A Practical Guide to Managing Diabetes with Insulin, and former Diabetes Educator of the Year, Scheiner joins Diabetes Dialogue to provide a deep dive into the largest diabetes meeting of the year from the view of a diabetes care and education specialist.
Investigators show a novel risk score helped define more than a dozen metabolites associated with the chronic sleep condition.
While young adults may be resistant to drinking interventions, improving sleep behavior can indirectly reduce hazardous drinking.
Mark Blumberg, MD, discusses his laboratory's particular interest in early REM sleep movement, and its potential impact on neurological disorders.
There are still many aspects of sleep health that need to be understood, especially in relation to the COVID-19 pandemic.
Investigators contribute more detailed understanding of the association between sleeping disorder and cardiovascular event risks.
Patients with diabetic retinopathy showed significantly higher updated first-year HbA1c and at follow-up compared to those free from DR.
Sleep issues are prevalent among children with autism or ADHD and both these common disorders are increasing. Any provider working with children is most likely going to encounter patients struggling with sleep.
A higher percentage of participants in the pooled dulaglutide group had a glycated hemoglobin level of <7.0% than the placebo group at week 26 of the AWARD-PEDS trial.
With this decision, dupilumab is now the only biologic medicine approved from infancy through adulthood for people with AD.
Late-breaking data from SLEEP 2022 show there may be biological plausibility for cardiovascular risks in excessively sleepy individuals.
The study from SLEEP 2022 is the first to explore directionality of sleep-stress relationships in a sample of perinatal women.
Even after controlling for differences in age and BMI, investigators observe a greater burden of sleep health on those who had severe COVID-19 versus the general population.
The late-breaking data show SGLT2is are underutilized in patients with heart failure with or without type 2 diabetes despite guideline recommendations.
